65G:F:F-NEXTCELL PHARMA AB (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.1155

Change

-0.01 (-6.85)%

Market Cap

USD 0.01B

Volume

2.00K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-02 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NOVA:F Novo Nordisk A/S

-1.00 (-0.94%)

USD 507.22B
NOV:F Novo Nordisk A/S

-1.44 (-1.36%)

USD 507.22B
RGO:F Regeneron Pharmaceuticals Inc

-6.20 (-0.65%)

USD 104.28B
CSJA:F CSL LTD SPON.ADR 2

N/A

USD 85.13B
CSJ:F CSL Limited

-0.22 (-0.12%)

USD 85.06B
DUL:F Alnylam Pharmaceuticals Inc

+2.10 (+0.86%)

USD 31.84B
UNC0:F UCB S.A. UNSP.ADR 1/2

+2.00 (+2.50%)

USD 30.73B
1AEA:F argenx SE

+8.00 (+1.67%)

USD 29.40B
1AE:F Argen-X

+7.70 (+1.59%)

USD 29.39B
22UA:F BioNTech SE

+0.20 (+0.19%)

USD 25.58B

ETFs Containing 65G:F

IQQ5:XETRA iShares MSCI Turkey UCITS.. 6.46 % 0.00 %

-0.70 (0%)

USD 0.10B
ITKY:LSE iShares II Public Limited.. 6.04 % 0.00 %

-61.50 (0%)

USD 0.11B
HTRY:SW 5.33 % 0.00 %

N/A

N/A
FEM:LSE First Trust Emerging Mark.. 1.40 % 0.00 %

+31.00 (+0%)

USD 0.01B
FEMU:LSE First Trust Global Funds .. 1.40 % 0.00 %

+0.29 (+0%)

USD 0.01B
FEM First Trust Emerging Mark.. 1.38 % 0.80 %

+0.25 (+0%)

USD 0.44B
TUR iShares MSCI Turkey ETF 0.00 % 0.59 %

-0.93 (0%)

N/A
HTRY:LSE 0.00 % 0.00 %

N/A

N/A
IDTK:LSE iShares MSCI Turkey UCITS 0.00 % 0.00 %

-0.49 (0%)

N/A
HTRD:LSE 0.00 % 0.00 %

N/A

N/A
HTR:PA 0.00 % 0.00 %

N/A

N/A
H4ZK:F 0.00 % 0.00 %

N/A

N/A
IQQ5:F iShares II Public Limited.. 0.00 % 0.00 %

-0.66 (0%)

N/A
H4ZK:XETRA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -41.81% 27% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -41.81% 27% F 10% F
Trailing 12 Months  
Capital Gain -53.61% 22% F 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -53.61% 22% F 8% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -28.21% N/A N/A 5% F
Dividend Return -28.21% N/A N/A 5% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 34.47% N/A N/A 35% F
Risk Adjusted Return -81.83% N/A N/A 6% D-
Market Capitalization 0.01B 20% F 12% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.